IDRSF
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.18 | $57M | -$28M |
| 2025 Q4 | -0.32 | $48M | -$46M |
| 2025 Q3 | -0.40 | $41M | -$21M |
| 2025 Q2 | -0.06 | $72M | -$45M |
| 2025 Q1 | 0.33 | $59M | -$61M |
| 2024 Q4 | -0.45 | $60M | -$12M |
| 2024 Q3 | -0.53 | $26M | -$145M |
| 2024 Q2 | -0.61 | $16M | -$112M |